Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Igor Odintsov
Clinicopathological and molecular features of uterine smooth muscle tumours in patients with Li-Fraumeni syndrome
Zehra Ordulu and David L Kolin contributed equally. Lin, L.H., Odintsov, I., Towery, E.A., Quade, B.J., Nucci, M.R., Ordulu, Z. and Kolin, D.L. (2026), Clinicopathological and molecular features of uterine smooth muscle tumours in patients with Li-Fraumeni syndrome. Histopathology. https://doi.org/10.1111/his.70201 Conflict of interest The authors declare no conflict of interest.
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer
|
Keywords small cell lung cancer natural killer cells STING agonism tumor-immune microenvironment spatial transcriptomics and proteomics 3D microphysiological systems Get full text access Log in, subscribe or purchase for full access. References 1. Burr, M.L. ∙ Sparbier, C.E. ∙ Chan, K.L. ... An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer Cancer Cell. 2019; 36:385-401.e8 2.
By Marco Campisi, Tatsuya Osaki, Ian D Dryg, Carla Stornante, Jacqueline C. Wolff, Jason L. Weirather, Mubin Tarannum, Ian Gillanders, Alan Bers, Eden Bobilev, Maia S. Lineberry, Pieter Schol, Minyue Chen, Keiichi Ota, Sung R. Park, Caroline G. Fahey, Tran C. Thai, Yixiang Li, Zhaorong Li, Ze-Hua Li, Satomi Hirose, Clare Padrick, Elena Ivanova, Minh Ha, Minh Châu-Thu Hà, Minh Trí-Kim Há, Shaobo Yang, Harrison Olszewski, Sophie Kivlehan, Patrick H. Lizotte, Kelsey Hagen, Iliana Gjeci, William Haller, Lauren M. Zasadil, Talal El Zarif, Jacob Berchuck, Erik H. Knelson, Elliott J. Brea, Igor Odintsov, Tianju Liu, Valeria Chiono, Bishma Tuladhar, Kenneth Ngo, Emily Rosentrater, Jeffrey J. Raizer, Neil Lineberry, Mriganka Sur, Kathleen L. Pfaff, Matthew Freedman, F. Stephen Hodi, Michael Y. Tolstorukov, Matthew G Oser, Michal Sheffer, Constantine S. Mitsiades, Michael Barnes Verified, Vicky A. Appleman, Prafulla C. Gokhale, Roger Kamm, Cloud Paweletz, Rizwan Romee, Scott J. Rodig, David A. Barbie, Navin R. Mahadevan
|
Cell Press
Verified
Cardiac epithelioid hemangioendothelioma with WWTR1::ACTL6A fusion and atypical histology mimicking cardiac angiosarcoma
Conflict of interest None of the authors has a conflict of interest to disclose. Supporting Information Filename Description his70087-sup-0001-Supplementary file 1.docxWord 2007 document , 16.1 KB File S1. his70087-sup-0002-Supplementary file 2.xlsExcel spreadsheet, 26 KB File S2. References 1, , et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 2011; 50; 644–653. 2, , .
Genetic correlates of malignancy in TFE3‐rearranged PEComa: a series of 14 cases
Aims Perivascular epithelioid cell tumours (PEComas) show variable smooth muscle and melanocytic differentiation and mostly harbour mTOR pathway activation via TSC2 inactivation. Five–10% of sporadic PEComas instead harbour fusions involving TFE3, an vmTOR pathway target. Malignancy in TSC2/1-inactivated PEComa correlates with TP53, RB1 or ATRX inactivation. Here, we investigated genetic correlates of malignancy in TFE3-rearranged PEComa.
Helsinn presents newly available data on vepafestinib at
Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer Lugano, Switzerland, August 8, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces its participation in the upcoming IASLC 2022 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, taking place from 6-9 August in Vienna, Austria.
New data on Helsinn’s oncology pipeline presented at Original
New data on Helsinn’s oncology pipeline presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022 Lugano, Switzerland, June 02, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces its participation in the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting which will be held from 3-7 June.
CIC-mediated modulation of MAPK signaling opposes receptor tyrosine kinase inhibitor response in kinase-addicted sarcoma
Research Article Igor Odintsov, Michael V Ortiz, Inna Khodos, Marissa S Mattar, Allan J.W Lui, Shinji Kohsaka, Elisa de Stanchina, Julia L Glade Bender, Marc Ladanyi and Romel Somwar DOI: 10.1158/0008-5472.CAN-21-1397 Abstract Kinase fusions have been identified in a growing subset of sarcomas, but a lack of preclinical models has impeded their functional analysis as therapeutic targets in the sarcoma setting.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Igor
Contact Igor, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack